
Picard Medical, Inc.
87
Recent news highlights Picard Medical's operational progress with revenue growth, narrowing losses, and advancements in artificial heart technology development, alongside regulatory and listing compliance actions.
- Picard Medical reported a 39% increase in Q2 revenue and a narrowing of net loss, leading to a 40% stock price jump [N6].
- The company advanced its artificial heart technology with successful in vivo implant studies for the Emperor Total Artificial Heart [N8].
- Picard Medical announced a 1-for-50 reverse stock split to comply with NYSE American listing requirements [N6].
- The company incorporated an extra design component into the SynCardia Total Artificial Heart design and presented data on the fully implantable Emperor Total Artificial Heart [N8].
- Picard Medical faces NYSE listing compliance challenges but has an accepted compliance plan with a deadline in November 2027 [S2].
Picard Medical, Inc. develops artificial heart technologies, including the Emperor Total Artificial Heart. The company is publicly traded on the NYSE American exchange under ticker PMI. It has reported recent revenue growth alongside net losses and is actively advancing its product development through in vivo implant studies and design enhancements. The company has taken steps to maintain its exchange listing through a reverse stock split and a compliance plan addressing equity and loss criteria.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Picard Medical, Inc. is a medical device company focused on artificial heart technology, reporting recent revenue growth and narrowing losses. The company faces NYSE listing compliance challenges but has submitted an accepted compliance plan. Recent news highlights operational progress including successful implant studies and design advancements [S1][S2][N6][N8].
Picard Medical has demonstrated operational progress with revenue growth and narrowing losses, supported by successful implant studies of its artificial heart technology. The company's acceptance of a compliance plan by NYSE American and strategic actions like a reverse stock split indicate management's commitment to maintaining market presence. Continued advancements in product design and clinical milestones could enhance its position in the artificial heart device market.
The company has reported net losses in multiple recent fiscal years and faces risks related to maintaining NYSE listing compliance due to equity and financial performance thresholds. Its liquidity ratios indicate tight short-term financial flexibility. Delisting risks could lead to reduced liquidity, limited market quotations, and challenges in obtaining financing. The capital-intensive nature of medical device development and regulatory hurdles add to execution risks.
Picard Medical's moat lies in its specialized development of artificial heart technology, including proprietary designs such as the Emperor Total Artificial Heart. Its progress in successful in vivo implant studies and incorporation of design improvements suggests a focus on innovation in a niche medical device market. However, the company operates in a highly regulated and capital-intensive industry with significant technological and clinical development challenges.
• NYSE Listing Compliance Risk: Picard Medical received a notice for non-compliance with NYSE American listing standards due to stockholders' equity and net losses, with a compliance plan accepted but no guarantee of regaining compliance by the November 2027 deadline [S2].
• Liquidity and Financial Risk: The company reported a current ratio below 1.0 and a very low cash ratio as of September 30, 2026, indicating limited short-term liquidity [S2].
• Operational and Development Risk: As a medical device company developing artificial heart technology, Picard Medical faces risks related to clinical development, regulatory approvals, and commercialization challenges.
Business trends: Continued advancement in artificial heart technology with revenue growth and narrowing losses.
Execution milestones: Successful in vivo implant studies, design enhancements, and NYSE compliance plan acceptance.
Key risks: Maintaining NYSE listing compliance, liquidity constraints, and clinical development uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Picard Medical, Inc. is a publicly traded company on the NYSE American exchange under the ticker PMI [S1].
- As of May 11, 2026, the company had 92,349,845 common shares outstanding [S1].
- The company reported stockholders' equity of $3.8 million as of December 31, 2025, and $1.3 million as of September 30, 2026 [S2].
- Picard Medical has experienced net losses in three of its four most recent fiscal years ending December 31, 2025 [S2].
- The company received a notice from the NYSE in May 2026 for non-compliance with listing standards due to stockholders' equity and net losses, and submitted a compliance plan accepted by NYSE American in July 2026 [S2].
- As of September 30, 2026, Picard Medical reported cash and cash equivalents of $67,000, current assets of $7,629,000, current liabilities of $7,734,000, a current ratio of 0.99, and a cash ratio of 0.01 [S2].
- For the quarter ended September 30, 2026, the company reported a net loss of $2,219,000 and basic EPS of -$0.95 [S2].
- The company reported revenue of $2,131,000 for the quarter ended June 30, 2025 [S2].
- Picard Medical is advancing development of artificial heart technology, including the Emperor Total Artificial Heart, with successful in vivo implant studies reported [N8][N6].
- The company announced a 1-for-50 reverse stock split in July 2026 to maintain NYSE American listing compliance [N6].
- Recent news highlights include a 40% stock price jump after Q2 revenue rose 39% and loss narrowed, indicating operational progress [N6].
- Picard Medical's business developments include incorporating extra design components into the SynCardia Total Artificial Heart design and presenting data on the fully implantable Emperor Total Artificial Heart [N8].
- The company faces risks related to compliance with NYSE listing standards and potential delisting consequences including reduced liquidity and financing challenges [S2].
Generated 2026-11-17
- S1 | 2026-05-14 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/lineage-cell-lctx-reports-q3-loss-misses-revenue-estimates
- N2 | 2026-11-09 | www.nasdaq.com | Claritev Corporation (CTEV) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/claritev-corporation-ctev-reports-q3-loss-tops-revenue-estimates
- N3 | 2026-11-05 | www.nasdaq.com | CareCloud, Inc. (CCLD) Tops Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/carecloud-inc-ccld-tops-q3-earnings-and-revenue-estimates
- N4 | 2026-11-03 | www.nasdaq.com | American Well Corporation (AMWL) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/american-well-corporation-amwl-reports-q3-loss-tops-revenue-estimates
- N5 | 2026-08-24 | www.nasdaq.com | Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains | https://www.nasdaq.com/articles/biotech-gainers-pmi-revenue-growth-sdot-earnings-surge-capr-fda-update-gri-data-drive
- N6 | 2026-08-24 | www.nasdaq.com | Picard Medical Stock Jumps 40% After Q2 Revenue Rises 39%; Loss Narrows | https://www.nasdaq.com/articles/picard-medical-stock-jumps-40-after-q2-revenue-rises-39-loss-narrows
- N7 | 2026-08-13 | www.nasdaq.com | Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/dare-bioscience-inc-dare-reports-q2-loss-beats-revenue-estimates
- N8 | 2026-06-03 | www.nasdaq.com | Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL | https://www.nasdaq.com/articles/top-biotech-gainers-pmi-advances-artificial-heart-cue-makes-board-changes-cing-despite-crl
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


